BACKGROUND: Early diagnosis and monitoring of disease activity are essential in cystic fibrosis (CF) and primary ciliary dyskinesia (PCD). We aimed to establish exhaled molecular profiles as the first step in assessing the potential of breath analysis. METHODS: Exhaled breath was analyzed by electronic nose in 25 children with CF, 25 with PCD and 23 controls. Principle component reduction and canonical discriminant analysis were used to construct internally cross-validated ROC curves. RESULTS: CF and PCD patients had significantly different breath profiles when compared to healthy controls (CF: sensitivity 84%, specificity 65%; PCD: sensitivity 88%, specificity 52%) and from each other (sensitivity 84%, specificity 60%). Patients with and without exacerbations had significantly different breath profiles (CF: sensitivity 89%, specificity 56%; PCD: sensitivity 100%, specificity 90%). CONCLUSION: Exhaled molecular profiles significantly differ between patients with CF, PCD and controls. The eNose may have potential in disease monitoring based on the influence of exacerbations on the VOC-profile.
BACKGROUND: Early diagnosis and monitoring of disease activity are essential in cystic fibrosis (CF) and primary ciliary dyskinesia (PCD). We aimed to establish exhaled molecular profiles as the first step in assessing the potential of breath analysis. METHODS: Exhaled breath was analyzed by electronic nose in 25 children with CF, 25 with PCD and 23 controls. Principle component reduction and canonical discriminant analysis were used to construct internally cross-validated ROC curves. RESULTS: CF and PCDpatients had significantly different breath profiles when compared to healthy controls (CF: sensitivity 84%, specificity 65%; PCD: sensitivity 88%, specificity 52%) and from each other (sensitivity 84%, specificity 60%). Patients with and without exacerbations had significantly different breath profiles (CF: sensitivity 89%, specificity 56%; PCD: sensitivity 100%, specificity 90%). CONCLUSION: Exhaled molecular profiles significantly differ between patients with CF, PCD and controls. The eNose may have potential in disease monitoring based on the influence of exacerbations on the VOC-profile.
Authors: K de Heer; M G M Kok; N Fens; E J M Weersink; A H Zwinderman; M P C van der Schee; C E Visser; M H J van Oers; P J Sterk Journal: J Clin Microbiol Date: 2015-12-16 Impact factor: 5.948
Authors: Odin Joensen; Tamara Paff; Eric G Haarman; Ib M Skovgaard; Peter Ø Jensen; Thomas Bjarnsholt; Kim G Nielsen Journal: PLoS One Date: 2014-12-26 Impact factor: 3.240
Authors: Pouline M P van Oort; Tamara Nijsen; Hans Weda; Hugo Knobel; Paul Dark; Timothy Felton; Nicholas J W Rattray; Oluwasola Lawal; Waqar Ahmed; Craig Portsmouth; Peter J Sterk; Marcus J Schultz; Tetyana Zakharkina; Antonio Artigas; Pedro Povoa; Ignacio Martin-Loeches; Stephen J Fowler; Lieuwe D J Bos Journal: BMC Pulm Med Date: 2017-01-03 Impact factor: 3.317
Authors: Rosa A Sola Martínez; José M Pastor Hernández; Óscar Yanes Torrado; Manuel Cánovas Díaz; Teresa de Diego Puente; María Vinaixa Crevillent Journal: Pediatr Res Date: 2020-09-12 Impact factor: 3.756
Authors: Adam J Shapiro; Maimoona A Zariwala; Thomas Ferkol; Stephanie D Davis; Scott D Sagel; Sharon D Dell; Margaret Rosenfeld; Kenneth N Olivier; Carlos Milla; Sam J Daniel; Adam J Kimple; Michele Manion; Michael R Knowles; Margaret W Leigh Journal: Pediatr Pulmonol Date: 2015-09-29